This involves thrombosis at unusual places in the body, associated with a low thrombocyte (blood platelet) count and a clotting disorder. In medical jargon, this syndrome is referred to as VITT (vaccine-induced thrombotic thrombocytopenia) or a vaccine-caused shortage of blood platelets. The VITT syndrome is most probably caused by a defective immune response, whereby thrombocyte-activating antibodies are produced resulting in thrombocytopenia (low platelet count) and thrombosis. The mortality rate in VITT is high (40-50 percent) and the syndrome requires immediate and appropriate treatment.
A team of doctors at the Department of Internal Medicine of the Medical University of Vienna (MedUni Vienna) and Vienna General Hospital successfully treated a patient suffering from vaccine-induced prothrombotic immune thrombocytopenia (VIPIT). The female patient was admitted to the department with a low platelet count and low fibrinogen levels, but still without a thrombosis. Fibrinogen is a protein that plays a major role in blood clotting. Indications of an impending thrombosis were extremely high, and doctors immediately began treatment with a high dose of intravenous immunoglobulin concentrates, cortisone and specific anticoagulants, so that thrombosis was prevented. These new findings were published in the Journal of Thrombosis and Haemostasis.
Read on and find out more about renowned research institutions in Austria!